Transcription factors bind to DNA and normally ensure that genes are expressed at the right time and in the right quantity. They have an important role in stem cell maintenance, cell maturation, and ensuring normal hematopoiesis. Mutations in the myeloid transcription factors, like CEBPA, RUNX1, and GATA2, occur in 20–25% of adults with AML. Currently, there are no specific therapeutic options for this molecular subgroup.